Entasis Therapeutics Holdings Inc.
ETTX
ETTX was delisted on the 8th of July, 2022.
30 hedge funds and large institutions have $19.6M invested in Entasis Therapeutics Holdings Inc. in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
36% more funds holding
Funds holding: 22 → 30 (+8)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
10% less capital invested
Capital invested by funds: $21.8M → $19.6M (-$2.21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$10M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$1.65M |
| 3 |
Renaissance Technologies
New York
|
+$409K |
| 4 |
Millennium Management
New York
|
+$359K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$172K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.93M |
| 2 |
Blackstone Inc
New York
|
-$2.23M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$479K |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$428K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$340K |
ETTX Hedge Fund Activity: Q3 2020 in Review
30 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Entasis Therapeutics Holdings Inc. (ETTX) for Q3 2020, worth a combined $19.6M — down 10% from $21.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ETTX positions and 3 closed out — a net gain of 8 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $10M. The largest seller was Novo Holdings A/S, cutting an estimated $2.93M.
- 30 institutional investors held Entasis Therapeutics Holdings Inc. (ETTX) as of Q3 2020, up from 22 in Q2 2020.
- Funds reported $19.6M of Entasis Therapeutics Holdings Inc. stock for Q3 2020, down 10% quarter-over-quarter.
- 11 funds opened new Entasis Therapeutics Holdings Inc. positions in Q3 2020 and 3 closed out, a net change of +8 holders.
- The largest Entasis Therapeutics Holdings Inc. buyer in Q3 2020 was Armistice Capital, an estimated $10M added.
- The largest Entasis Therapeutics Holdings Inc. seller in Q3 2020 was Novo Holdings A/S, an estimated $2.93M sold.
Based on aggregated 13F filings for Q3 2020.